MADHAVBAUG

Vaidya Sane Ayurved Laboratories Share Price

₹156.75 +6.95 (4.64%)

Stock Hit Upper Circuit

24 Jun, 2025 10:36

SIP TrendupStart SIP in MADHAVBAUG

Start SIP

Performance

  • Low
  • ₹155
  • High
  • ₹157
  • 52 Week Low
  • ₹81
  • 52 Week High
  • ₹178
  • Open Price₹157
  • Previous Close₹150
  • Volume1,600

Investment Returns

  • Over 1 Month + 8.59%
  • Over 3 Month + 49.43%
  • Over 6 Month + 12.93%
  • Over 1 Year -2.03%
SIP Lightning

Smart Investing Starts Here Start SIP with Vaidya Sane Ayurved Laboratories for Steady Growth!

Invest Now

Vaidya Sane Ayurved Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 23.1
  • PEG Ratio
  • -
  • Market Cap Cr
  • 165
  • P/B Ratio
  • 3.6
  • Average True Range
  • 7.42
  • EPS
  • 7.61
  • Dividend Yield
  • 0
  • MACD Signal
  • 7.36
  • RSI
  • 52.5
  • MFI
  • 79.48

Vaidya Sane Ayurved Laboratories Financials

Vaidya Sane Ayurved Laboratories Technicals

EMA & SMA

Current Price
₹156.75
+ 6.95 (4.64%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹150.22
  • 50 Day
  • ₹138.74
  • 100 Day
  • ₹133.15
  • 200 Day
  • ₹139.82

Resistance and Support

148.27 Pivot Speed
  • R3 161.03
  • R2 156.27
  • R1 153.03
  • S1 145.03
  • S2 140.27
  • S3 137.03

What's your outlook on Vaidya Sane Ayurved Laboratories?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vaidya Sane Ayurved Laboratories has an operating revenue of Rs. 198.66 Cr. on a trailing 12-month basis. An annual revenue de-growth of -9% needs improvement, Pre-tax margin of 11% is healthy, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 13% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 47 indicates it belongs to a fair industry group of Medical-Hospitals and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vaidya Sane Ayurved Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-22 Audited Results (Revised)
2024-11-11 Quarterly Results & Others To consider other business matters.
2024-05-26 Audited Results
2023-05-27 Audited Results & Dividend
2022-11-10 Quarterly Results
Date Purpose Remarks
2022-11-18 INTERIM Declaration of Interim dividend at the rate of 0.25 per share {2.5%}.
View More

Vaidya Sane Ayurved Laboratories F&O

Vaidya Sane Ayurved Laboratories Shareholding Pattern

66.34%
21.94%
11.72%

About Vaidya Sane Ayurved Laboratories

  • NSE Symbol
  • MADHAVBAUG
  • BSE Symbol
  • Managing Director
  • Dr. Rohit Madhav Sane
  • ISIN
  • INE0JR301013

Similar Stocks to Vaidya Sane Ayurved Laboratories

Vaidya Sane Ayurved Laboratories FAQs

Vaidya Sane Ayurved Laboratories share price is ₹156 As on 24 June, 2025 | 10:22

The Market Cap of Vaidya Sane Ayurved Laboratories is ₹164.8 Cr As on 24 June, 2025 | 10:22

The P/E ratio of Vaidya Sane Ayurved Laboratories is 23.1 As on 24 June, 2025 | 10:22

The PB ratio of Vaidya Sane Ayurved Laboratories is 3.6 As on 24 June, 2025 | 10:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23